Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD

Ruxolitinib has become a new therapeutic option for steroid refractory graft-versus-host disease (srGVHD), with a substantial remission rate. Its anti-inflammatory properties by blocking interleukin pathways have made it a novel therapeutic approach to inflammatory disease processes, such as GVHD. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Sobash, Philip T., Guddati, Achuta K., Kota, Vamsi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7166298/
https://www.ncbi.nlm.nih.gov/pubmed/32318300
http://dx.doi.org/10.1155/2020/4936846

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7166298/
https://www.ncbi.nlm.nih.gov/pubmed/32318300
http://dx.doi.org/10.1155/2020/4936846

Ejemplares similares